EUVIMEDEUVIMED entdecken
Crossref

Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China

Peijiang Pan, Caichang Mo, Rongfeng Chen, Yanyan Liao, Bingyu Liang, Xiaomei Li, Qisi Su, Yuanting Li, Feirong Chen, Yifeng Huang, Hailong Wang, Lijuan Zhou und 4 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Peijiang Pan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Guangxi, Nanning 530021, China. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, HIV Infections, Anti-HIV Agents. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Key R&D Program of China, Guangxi Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Lenacapavir, a first-in-class, long-acting capsid inhibitor (CAI), has been approved for HIV-1 treatment and prevention. However, naturally occurring resistance to the HIV-1 CAI at the quasi-species level is rarely reported.

Methods

Using next-generation sequencing (NGS), we obtained 495 HIV-1 near-full-length genome (NFLG) sequences derived from plasma specimens of ART-naive individuals in Guangxi, China. Drug resistance mutations (DRMs) conferring resistance to CAIs, as well as to NNRTIs, NRTIs, PIs and INSTIs, were detected at a 5% frequency threshold for variant calling using the HIVdb program. To analyse naturally occurring polymorphisms, the gag sequences of CRF08_Bc subtype were retrieved from two public sequence databases, followed by CAI-related DRM detection. Subtype-specific capsid polymorphism was analysed with a 0.5% prevalence cut-off.

Results

Of the 495 individuals, 16.77% (83/495) were infected with unique recombinant forms (URFs). Overall, 4.44% (22/495) of the sequences were carrying at least DRMs to CAIs, including one major DRM (Q67H, 0.80%) and two accessory DRMs (T107A, 2.22%; T107S, 1.81%). No cross-resistance to other classes of drugs, including PIs, NRTIs, NNRTIs or INSTIs, was observed in individuals with CAI-related DRMs. According to the definition of subtype-specific polymorphism (>0.5% prevalence), Q67H (1.60%, 3/188) and T107S (1.60%, 3/188) were CRF01_AE-specific polymorphisms, whereas T107A (5.05%, 11/218) and T107S (3.03%, 5/218) were CRF08_Bc-specific polymorphisms.

Conclusions

HIV URFs are commonly misclassified by conventional partial pol gene subtyping among treatment-naive patients in Guangxi, indicating a need for enhanced full-genome genotyping surveillance locally. Subtype-specific capsid polymorphisms that have not been identified in previous studies further highlight the value of geographically diverse cohorts in future CAI research to improve real-world applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Drug Resistance, ViralHIV InfectionsAnti-HIV AgentsCapsidHumansChinaHigh-Throughput Nucleotide SequencingGenome, ViralGenotypePolymorphism, GeneticFemaleMaleAdult

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Guangxi, Nanning 530021, China.
  • Biosafety III Laboratory, Life Science Institute, Guangxi Medical University, Guangxi, Nanning 530021, China.
  • Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-Association of Southeast Asian Nations, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.
  • Department of Infectious Diseases, Nanning Fourth People's Hospital, Guangxi, Nanning 530012, China.
  • Liuzhou Key Laboratory of Infectious Disease Immunity Research & Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Guangxi, Liuzhou 545005, China.

ORCID-Profile: Junjun Jiang, Li Ye, Hao Liang

Förderung

  • National Key R&D Program of China
  • Guangxi Natural Science Foundation
  • National Natural Science Foundation of China
  • Innovative Research Team Project of Guangxi Natural Science Foundation
  • Guangxi Medical University Training Program for Young Leading Talents
  • Key Laboratory Open Topic of Liuzhou Key Laboratory of Infectious Disease Immunity Research
  • Guangxi Health Commission Key Laboratory of Clinical Biotechnology
  • Innovation Project of Guangxi Graduate Education

Zitieren

APA

Pan, P., Mo, C., Chen, R., Liao, Y., Liang, B., Li, X., Su, Q., Li, Y., Chen, F., Huang, Y., Wang, H., Zhou, L., Li, X., Jiang, J., Ye, L., & Liang, H. (2026). Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag334

Vancouver

Pan P, Mo C, Chen R, Liao Y, Liang B, Li X, et al. Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag334

BibTeX
@article{Pan2026,
  author = {Pan, Peijiang and Mo, Caichang and Chen, Rongfeng and Liao, Yanyan and Liang, Bingyu and Li, Xiaomei and Su, Qisi and Li, Yuanting and Chen, Feirong and Huang, Yifeng and Wang, Hailong and Zhou, Lijuan and Li, Xu and Jiang, Junjun and Ye, Li and Liang, Hao},
  title = {Evaluation of capsid inhibitor resistance profiles and HIV-1 subtype distribution via near-full-length genome NGS in ART-naive HIV-1 patients in Guangxi, China},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag334}
}
Kostenlos starten →